Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

For this sub-study, you will be assigned to treatment with talazoparib (BMN 673), a PARP inhibitor. The purpose of this sub-study is to find any good and bad effects of talazoparib (BMN 673). Talazoparib (BMN 673) may or may not shrink your cancer and it could also cause side effects.


This research study is led by Dr. John McCann.

Contact: Katie Colbeck, 413-794-9875

Participation details:

Cancer, Cancer - Lung

D'Amour Center for Cancer Care, 3350 Main Street, Springfield, MA 01199

Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer